Atopic Dermatitis Market

Atopic Dermatitis Market Analysis By Drug Class (Corticosteroids, PDE4 Inhibitors, Biologics, Skin Barrier Emollients, CNI Immunosuppressants, Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) & By Region - Global Market Insights 2022 to 2032

Analysis of Atopic Dermatitis Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Table of Content

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Market Analysis and Forecasts, 2022–2032

5. Market Outlook

    5.1. Disease Epidemiology

    5.2. Pipeline Analysis

    5.3. Recent Development

6. Global Market Analysis and Forecasts, by Drug Class

    6.1. Introduction & Definition

    6.2. Market Value Forecast by Drug Class, 2022–2032

        6.2.1. Corticosteroids

        6.2.2. PDE4 Inhibitors

        6.2.3. Biologics

        6.2.4. Skin Barrier Emollients

        6.2.5. CNI Immunosuppressants

        6.2.6. Others

    6.3. Market Attractiveness by Drug Class

7. Global Market Analysis and Forecasts, by Distribution Channel

    7.1. Introduction & Definition

    7.2. Market Value Forecast by Distribution Channel, 2022–2032

        7.2.1. Hospital Pharmacies

        7.2.2. Retail Pharmacies

        7.2.3. Online Pharmacies

    7.3. Market Attractiveness by Distribution Channel

8. Global Market Analysis and Forecasts, by Region

    8.1. Key Findings

    8.2. Market Value Forecast by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness by Country/Region

9. North America Market Analysis and Forecast

    9.1. Introduction

    9.2. Market Value Forecast by Drug Class, 2022–2032

        9.2.1. Corticosteroids

        9.2.2. PDE4 Inhibitors

        9.2.3. Biologics

        9.2.4. Skin Barrier Emollients

        9.2.5. CNI Immunosuppressants

        9.2.6. Others

    9.3. Market Value Forecast by Distribution Channel, 2022–2032

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. Market Value Forecast by Country, 2022–2032

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Drug Class

        9.5.2. By Distribution Channel

        9.5.3. By Country

10. Europe Market Analysis and Forecast

    10.1. Introduction

    10.2. Market Value Forecast by Drug Class, 2022–2032

        10.2.1. Corticosteroids

        10.2.2. PDE4 Inhibitors

        10.2.3. Biologics

        10.2.4. Skin Barrier Emollients

        10.2.5. CNI Immunosuppressants

        10.2.6. Others

    10.3. Market Value Forecast by Distribution Channel, 2022–2032

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

    10.4. Market Value Forecast by Country/Sub-region, 2022–2032

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Drug Class

        10.5.2. By Distribution Channel

        10.5.3. By Country/Sub-region

11. Asia Pacific Market Analysis and Forecast

    11.1. Introduction

    11.2. Market Value Forecast by Drug Class, 2022–2032

        11.2.1. Corticosteroids

        11.2.2. PDE4 Inhibitors

        11.2.3. Biologics

        11.2.4. Skin Barrier Emollients

        11.2.5. CNI Immunosuppressants

        11.2.6. Others

    11.3. Market Value Forecast by Distribution Channel, 2022–2032

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Online Pharmacies

    11.4. Market Value Forecast by Country/Sub-region, 2022–2032

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis

        11.5.1. By Drug Class

        11.5.2. By Distribution Channel

        11.5.3. By Country/Sub-region

12. Latin America Market Analysis and Forecast

    12.1. Introduction

    12.2. Market Value Forecast by Drug Class, 2022–2032

        12.2.1. Corticosteroids

        12.2.2. PDE4 Inhibitors

        12.2.3. Biologics

        12.2.4. Skin Barrier Emollients

        12.2.5. CNI Immunosuppressants

        12.2.6. Others

    12.3. Market Value Forecast by Distribution Channel, 2022–2032

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Online Pharmacies

    12.4. Market Value Forecast by Country/Sub-region, 2022–2032

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis

        12.5.1. By Drug Class

        12.5.2. By Distribution Channel

        12.5.3. By Country/Sub-region

13. Middle East & Africa Market Analysis and Forecast

    13.1. Introduction

    13.2. Market Value Forecast by Drug Class, 2022–2032

        13.2.1. Corticosteroids

        13.2.2. PDE4 Inhibitors

        13.2.3. Biologics

        13.2.4. Skin Barrier Emollients

        13.2.5. CNI Immunosuppressants

        13.2.6. Others

    13.3. Market Value Forecast by Distribution Channel, 2022–2032

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies

        13.3.3. Online Pharmacies

    13.4. Market Value Forecast by Country/Sub-region, 2022–2032

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis

        13.5.1. By Drug Class

        13.5.2. By Distribution Channel

        13.5.3. By Country/Sub-region

14. Competitive Landscape

    14.1. Company Profiles

        14.1.1. Mylan N.V.

            14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.1.1.2. Product Portfolio

            14.1.1.3. SWOT Analysis

            14.1.1.4. Strategic Overview

            14.1.1.5. Financial Overview

        14.1.2. Pfizer, Inc.

            14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.1.2.2. Product Portfolio

            14.1.2.3. SWOT Analysis

            14.1.2.4. Strategic Overview

            14.1.2.5. Financial Overview

        14.1.3. LEO Pharma A/S

            14.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.1.3.2. Product Portfolio

            14.1.3.3. SWOT Analysis

            14.1.3.4. Strategic Overview

            14.1.3.5. Financial Overview

        14.1.4. Teva Pharmaceutical Industries Ltd

            14.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.1.4.2. Product Portfolio

            14.1.4.3. SWOT Analysis

            14.1.4.4. Strategic Overview

            14.1.4.5. Financial Overview

        14.1.5. Sanofi

            14.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.1.5.2. Product Portfolio

            14.1.5.3. SWOT Analysis

            14.1.5.4. Strategic Overview

            14.1.5.5. Financial Overview

        14.1.6. Novartis AG

            14.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.1.6.2. Product Portfolio

            14.1.6.3. SWOT Analysis

            14.1.6.4. Strategic Overview

            14.1.6.5. Financial Overview

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: Global Market Value (US$ Mn) Forecast, by Drug Class, 2022–2032

Table 02: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2022–2032

Table 03: Global Market Value (US$ Mn) Forecast, by Region, 2022–2032

Table 04: North America Market Value (US$ Mn) Forecast, by Country, 2022–2032

Table 05: North America Value (US$ Mn) Forecast, by Drug Class, 2022–2032

Table 06: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2022–2032

Table 07: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022–2032

Table 08: Europe Value (US$ Mn) Forecast, by Drug Class, 2022–2032

Table 09: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2022–2032

Table 10: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022–2032

Table 11: Asia Pacific Value (US$ Mn) Forecast, by Drug Class, 2022–2032

Table 12: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2022–2032

Table 13: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022–2032

Table 14: Latin America Value (US$ Mn) Forecast, by Drug Class, 2022–2032

Table 15: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2022–2032

Table 16: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022–2032

Table 17: Middle East & Africa Value (US$ Mn) Forecast, by Drug Class, 2022–2032

Table 18: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2022–2032

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 01: Global Market Snapshot

Figure 02: Global Market Value (US$ Mn) and Distribution, by Region, 2022 and 2027

Figure 03: Global Market Value (US$ Mn) Forecast, 2022–2032

Figure 04: Global Market Value Share (%), by Drug Class (2022)

Figure 05: Global Market Value Share (%), by Distribution Channel (2022)

Figure 06: Global Market Value Share (%), by Region (2022)

Figure 07: Global Market Value Share Analysis, by Drug Class, 2022 and 2027

Figure 08: Global Market Attractiveness, by Drug Class, 2022–2027

Figure 09: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2022–2032

Figure 10: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by PDE4 Inhibitors, 2022–2032

Figure 11: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biologics, 2022–2032

Figure 12: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Skin Barrier Emollients, 2022–2032

Figure 13: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by CNI Immunosuppressants, 2022–2032

Figure 14: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2022–2032

Figure 15: Global Market Value Share (%), by Distribution Channel, 2022 and 2027

Figure 16: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2022–2032

Figure 17: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2022–2032

Figure 18: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2022–2032

Figure 19: Global Market Attractiveness, by Distribution Channel, 2022–2027

Figure 20: Global Market Value Share Analysis, by Region, 2022 and 2027

Figure 21: Global Market Attractiveness, by Region, 2022–2027

Figure 22: North America Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2032

Figure 23: North America Market Value Share (%), by Country, 2022 and 2027

Figure 24: North America Market Attractiveness, by Country, 2022–2027

Figure 25: North America Market Value Share (%), by Drug Class, 2022 and 2027

Figure 26: North America Market Attractiveness, by Drug Class, 2022–2027

Figure 27: North America Market Value Share (%), by Distribution Channel, 2022 and 2027

Figure 28: North America Market Attractiveness, by Distribution Channel, 2022–2027

Figure 29: Europe Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2032

Figure 30: Europe Market Value Share (%), by Country/Sub-region, 2022 and 2027

Figure 31: Europe Market Attractiveness, by Country/Sub-region, 2022–2027

Figure 32: Europe Market Value Share (%), by Drug Class, 2022 and 2027

Figure 33: Europe Market Attractiveness, by Drug Class, 2022–2027

Figure 34: Europe Market Value Share (%), by Distribution Channel, 2022 and 2027

Figure 35: Europe Market Attractiveness, by Distribution Channel, 2022–2027

Figure 36: Asia Pacific Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2032

Figure 37: Asia Pacific Market Value Share (%), by Country/Sub-region, 2022 and 2027

Figure 38: Asia Pacific Market Attractiveness, by Country/Sub-region, 2022–2027

Figure 39: Asia Pacific Market Value Share (%), by Drug Class, 2022 and 2027

Figure 40: Asia Pacific Market Attractiveness, by Drug Class, 2022–2027

Figure 41: Asia Pacific Market Value Share (%), by Distribution Channel, 2022 and 2027

Figure 42: Asia Pacific Market Attractiveness, by Distribution Channel, 2022–2027

Figure 43: Latin America Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020-2027

Figure 44: Latin America Market Value Share (%), by Country/Sub-region 2022 and 2027

Figure 45: Latin America Market Attractiveness, by Country/Sub-region, 2022–2027

Figure 46: Latin America Market Value Share (%), by Drug Class, 2022 and 2027

Figure 47: Latin America Market Attractiveness, by Drug Class, 2022–2027

Figure 48: Latin America Market Value Share (%), by Distribution Channel, 2022 and 2027

Figure 49: Latin America Market Attractiveness, by Distribution Channel, 2022–2027

Figure 50: Middle East & Africa Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022–2032

Figure 51: Middle East & Africa Market Value Share (%), by Country/Sub-region 2022 and 2032

Figure 52: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2022–2032

Figure 53: Middle East & Africa Market Value Share (%), by Drug Class, 2022 and 2032

Figure 54: Middle East & Africa Market Attractiveness, by Drug Class, 2022–2032

Figure 55: Middle East & Africa Market Value Share (%), by Distribution Channel, 2022 and 2032

Figure 56: Middle East & Africa Market Attractiveness, by Distribution Channel, 2022–2032

Figure 57: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2021

Figure 58: Mylan N.V. R&D Expenses (US$ Mn), 2016–2018

Figure 59: Mylan N.V.  Breakdown of Net Sales (%), by Region, 2018

Figure 60: Mylan N.V. Breakdown of Net Sales (%), by Business Segment, 2018

Figure 61: Pfizer, Inc. Breakdown of Net Sales, by Region, 2018

Figure 62: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2018

Figure 63: Pfizer, Inc. R&D Expenses (US$ Mn), 2016–2018

Figure 64: LEO Pharma A/S Breakdown of Net Sales, by Region (2018)

Figure 65: LEO Pharma A/S Breakdown of Net Sales, by Therapeutic Area (2018)

Figure 66: LEO Pharma A/S Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2018

Figure 67: LEO Pharma A/S R&D Expenses (US$ Mn), 2016–2018

Figure 68: Sanofi Revenue (US$ Bn), 2015–2018

Figure 69: Sanofi Regional Sales Breakdown (%), 2018

Figure 70: Novartis AG Breakdown of Net Sales, by Region, 2018

Figure 71: Novartis AG Breakdown of Net Sales, by Business Segment, 2018

Figure 72: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

Figure 73: Novartis AG R&D Expenses (US$ Mn), 2016–2018

Figure 74: Teva Pharmaceutical Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2018

Figure 75: Teva Pharmaceutical R&D Expenses (US$ Mn), 2016–2018

Figure 76: Teva Pharmaceutical Breakdown of Net Sales, by Region, 2018

Figure 77: Teva Pharmaceutical Breakdown of Net Sales, (Overall Company Level), 2018

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Atopic Dermatitis Market

Schedule a Call

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.

By clicking "Accept All", you consent to our use of cookies. Privacy Policy